SIGNIFICANCE OF VASCULAR ENDOTHELIUM GROWTH FACTOR IN ENDOTHELIAL DYSFUNCTION AMONG PATIENTS WITH METABOLIC SYNDROME

Abstract

Aim. The objective of our study was to investigate the status of endothelium in patients with metabolic syndrome. Metabolic syndrome (MS) is a block of hormonal and metabolic disorders united by a common pathophysiological mechanism - insulin resistance (IR). The connecting link between IR and cardiovascular diseases is endothelial dysfunction. Materials and methods. The problem was solved by means of assessment of vascular tonus changes using skin temperature range wavelet-analysis and VEGF determination while performing indirect cold test. Results. Serum VEGF concentration in MS patients was reliably higher than in practically healthy persons. In patients with MS, cold test response significantly differed from the control group. While carrying out cold test, the amplitude reliably decreased in endothelial and neurogenic bandwidth without its rise by the end of the study. There was revealed a reliable direct correlation between VEGF and BMI ( r =0,59; p <0,05), VEGF and WC ( r =0,58; p <0,05), VEGF and DAP ( r =0,57; p <0,05), VEGF and total cholesterol levels ( r =0,74; p <0,05). Conclusion. Thus, endothelial dysfunction in MS patients is displayed by impaired vasodilation in physiological cold test, but increase in patients’ VEGF level can be considered as an additional marker of cardiovascular risk.

References

  1. Коваль С. Н. Снегурская И. А., Мысниченко О. В. Семейство васкулоэндотелиального фактора роста и его возможная роль в патогенезе артериальных гипертензий. Артериальная гипертензия 2012; 4 (24): 36-41.
  2. Рекалов Д. Г. Особенности метаболизма факторов роста у пациентов с гипертонической болезнью. Материалы науч.-практ. конф. с междунар. участием. Харков 2004; 83-84.
  3. Смирнова Е. Н., Подтаев С. Ю., Мизева И. А., Жукова Е. А. Нарушение механизмов вазодилатации у больных сахарным диабетом 2-го типа при проведении контралатеральной холодовой пробы. Регионарное кровообращение и микроциркуляция. Пермь 2012; 11 (1 (41)): 30-34.
  4. He H., Venema V. J., Gu X. [et al.] Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 1999; 274: 25130-25135.
  5. Smirnova E., Podtaev S., Mizeva I., Loran E. Assessment of endothelial dysfunction in patients with impaired glucose tolerance during a cold pressor test. Diabetes and Vascular Disease Research 2013; August: 1-9.
  6. Trape J. C., Morales R., Molina X. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand. J. Clin. Lab. Invest. 2006; 663: 261-267.
  7. Vyzantiadis T., Karagiannis A., Douma S., Harsoulis P., Vyzantiadis A., Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin. Exp. Hypertens 2006; 28 (7): 603-609.
  8. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997; 420: 28-32.

Comments on this article


Copyright (c) 2014 Shulkina S.G., Loran E.A., Smirnova E.N., Turuntseva O.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies